Currently, the workup for metastatic disease recommends the investigation of activating mutations in KRAS (exon 2, 3, or 4) or NRAS (exon 2, 3 or 4) and BRAF (V600E), as well MMR status [20]. Here, NRAS is linked to metastatic neoplasm.